Precision Medicine Suites for Difficult Cases · Cross-Domain Systems Biology · 11 Dedicated Specialties
11 Dedicated Precision Suites. The collective intelligence of an entire consilium, mobilized for your family.
Intractable chronic illness does not yield to fifteen-minute consultations. It does not yield to trial-and-error polypharmacy. It yields to depth, to cross-domain synthesis, to an intelligence that never sleeps and never forgets a data point. DeepSensi™ Precision Suites deliver exactly that: eleven advanced cognitive intelligence platforms, one dedicated to each major disease category, uniting our Dual Pathway engine, the MASAI Digital Twin, and DSS-001 multi-source verified clinical decision dossiers, built for your treating physician. Not for time-critical or emergency decisions. The software does not monitor anyone, sends no alerts and no notifications, and has no time-based triggers.
Precision Suites in the United States: reservations open shortly. Precision Suites launch in the United States in October 2026. Other countries will be activated one by one. Reservations will set the order.
$4,850 $790
Case Intake & 12-Month Longitudinal Access
11 Suites
specialized disease engines
100% Free
RESOLVE™ registry participation
Platform Architecture · Regulatory Transparency
A Cognitive Intelligence Operating System (Software & Decision Support)
Precision Suite is clinical decision support software for licensed physicians. We believe it meets the non-device criteria of section 520(o)(1)(E) of the FD&C Act. FDA has not reviewed or confirmed this. It has not been cleared, approved, or otherwise authorized by FDA, and it makes no diagnostic accuracy claims. Regulatory status: deepsensi.com/regulatory The Precision Suite™ Protocol intake and 12-month longitudinal access (Standard Institutional Value: $4,850, subsidized to $790 under the DeepSensi PBC Public Benefit Charter for registered protocol participants) provides access to the Difficult Cases Engine, personalized MASAI Digital Twin modeling, and continuous multi-system tensor synthesis. Not for time-critical or emergency decisions. The software membership does not include physical laboratory testing kits; caregivers and patients upload routine and specialized lab results (Organic Acids Tests, stool metagenomics, blood smears, therapeutic drug levels) performed at any accredited laboratory the patient and their physician choose.
Disease-Specific Suites
Eleven specialized precision medicine platforms
Modern medicine is organized into silos. A neurologist reads the brain. A gastroenterologist reads the gut. A geneticist reads the genome. A pharmacologist reads the drug. Each sees a fragment. None sees the whole. And in chronic, intractable illness, the answer almost never lives inside a single fragment.
DeepSensi was built to break those silos: not by adding another specialist, but by adding a new kind of reasoning. At the core of every Precision Suite runs the DeepSensi Cognitive Engine, a cross-disciplinary deduction system that holds the entire clinical record at once: laboratory values, written reports, medication levels, genomic findings, microbial pathways, metabolic markers, treatment history, and the published literature. It does not read them in sequence. It reads them in relation.
This is where the unprecedented part begins. The Cognitive Engine performs interdisciplinary and cross-system deduction at a scale and speed no human consilium can match. It asks questions that no single specialty would think to ask: How does a microbial metabolite in the gut alter the clearance of a drug acting in the brain? How does an inherited variant in one pathway amplify a toxicity that only appears when a second pathway is blocked? How does an inflammatory signal from the mucosa change the pharmacokinetics of a medicine prescribed for an entirely different organ system?
Laboratory tests are ordered by you and your own physician at a laboratory of your choice. A Suite reads the written reports.
It does not stop at correlation. It builds mechanistic hypotheses: traceable, sourced, and ready for the physician to test. And in doing so, it surfaces the correlations that were always there, hidden in plain sight, overlooked because no one was looking across all systems at once.
The result is a dossier for the treating physician that is not a summary but a synthesis. A multidimensional map of the patient’s biology where every conclusion can be followed back to its origin. Next to the reported medicine levels it sets out the published data on interactions and clearance. It computes no individual pharmacokinetic model and gives no dose. The physician receives hypotheses and suggestions to consider, each with the data and the published sources it rests on.
In the EPI, NEURO, MIND and PSYCH Suites, the analysis also maps, with sources, how microbial pathways that make or consume neurotransmitter precursors (tryptophan, tyrosine, glutamate) relate to the urinary metabolite levels in the same record (5-HIAA, homovanillic acid, kynurenine, quinolinic acid), for the physician to review. It reads written reports and values, never raw sequencing files, images or device exports.
OSF RESEARCH COHORT (N=10,000) — PROTOCOL ALLOCATION
Precision Suite™ Protocol
Comprehensive Cognitive Case Dossier + 12-Month Decentralized Registry Access
Standard Institutional Value:$4,850
$790/ Case Intake & 1-Yr Tracking
*Subsidized under the DeepSensi PBC Public Benefit Charter for registered protocol participants.
Full Multimodal Tensor Synthesis: AI integration of patient-provided OAT, Metagenomic Stool Microbiome, Marrow Kinetics & Pharmacogenomics.
For drug-resistant, pediatric, and developmental encephalopathies
Decomposes the gut-brain axis, clostridial neurotoxins (HPHPA, 4-cresol), mitochondrial uncoupling, and antiepileptic drug pharmacokinetic compounding: the forces that keep seizures coming back.
DeepSensi Dual Pathway & Consilium DDx Engine
MASAI Digital Twin seizure trajectory mapping
TDM polypharmacy de-compounding tensor
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
Gut-brain axis mapping: neurotransmitter precursors, metabolite levels, and their correlations
For regressive ASD, PANDAS/PANS, ME-CFS & Neuro Long COVID
Maps systemic neuroinflammatory cascades, tryptophan-kynurenine diversion, cerebral folate transport, and intestinal permeability: the full terrain of neurocognitive injury, charted for recovery.
Dual Pathway caregiver + clinician cockpits
ATEC / CY-BOCS behavioral trajectory tracking Requires FDA authorizationNot available in your region yet
Neuro-cytokine and metabolome correlation Requires FDA authorizationNot available in your region yet
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
Gut-brain axis mapping: neurotransmitter precursors, metabolite levels, and their correlations
For Crohn's, Colitis, Systemic Lupus & Multiple Sclerosis
Identifies microbial mimicry triggers, mucosal barrier breakdown, and cellular immunometabolic imbalance: the roots of autoimmune fire, targeted to support steroid-free clinical remission.
Dual Pathway mucosal & autoimmune analytics
Serial calprotectin & inflammatory kinetic curves
Biologic and immunosuppressive response tracking Requires FDA authorizationNot available in your region yet
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
For chemotherapy marrow preservation & metabolic resilience
Monitors hematologic nadir trajectories, drug-drug competitive clearance, and cellular bioenergetics, so full relative dose intensity (RDI ≥ 85%) can be sustained without debilitating toxicities. Not for time-critical or emergency decisions.
For POTS, dysautonomia, channelopathies & cardiomyopathies
Combines autonomic tilt-table hemodynamics, advanced particle lipidomics (Lp(a), ApoB, LDL-P), and ion channel drug-safety tensors (KCNQ1, SCN5A) under architected deterministic bounds. Not for time-critical or emergency decisions.
Dual Pathway cardiology & POTS cockpit
Autonomic catecholamine & orthostatic stability twin Requires FDA authorizationNot available in your region yet
hs-cTnI, NT-proBNP & lipidomic kinetic mapping Requires FDA authorizationNot available in your region yet
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
For undiagnosed pediatric syndromes & N=1 orphan mutations
Synthesizes Human Phenotype Ontology (HPO) deep graphs, whole-genome trio re-analysis, and DNA methylation episignatures, reclassifying variants of uncertain significance and surfacing actionable metabolic bypasses where none were thought to exist.
Dual Pathway orphan genomics & consilium cockpit
Multi-omic tensor T_rare simulation engine Requires FDA authorizationNot available in your region yet
Automated ACMG variant re-classification pipeline Requires FDA authorizationNot available in your region yet
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
For deep infiltrating endometriosis, adenomyosis & refractory PCOS
Maps systemic peritoneal neuro-inflammation, VEGF/TNF-alpha angiogenic cytokine cascades, and estrobolome microbial beta-glucuronidase genomics, closing the 7-10 year diagnostic void that has left too many women without answers.
Peritoneal cytokine tensor & estrobolome metagenomic profiling Requires FDA authorizationNot available in your region yet
MASAI Digital Twin endocrine-metabolic simulation
Angiogenic & chronic pelvic pain de-escalation protocol Requires FDA authorizationNot available in your region yet
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
For Treatment-Resistant Depression (TRD) & gut-brain neuroinflammation
Deconstructs tryptophan-kynurenine diversion, quinolinic acid neurotoxicity, microglial activation, and CYP2D6/CYP2C19 pharmacogenomic bottlenecks in psychiatric polypharmacy. Not for time-critical or emergency decisions.
Kynurenine/tryptophan neurotoxicity ratio modeling Requires FDA authorizationNot available in your region yet
For psychiatric genomics and the pharmacogenomics of psychotropic medicines
Polygenic risk across psychiatric conditions, serotonin and dopamine pathway genes, and pharmacogenomics of psychotropic medicines. Not for time-critical or emergency decisions.
Polygenic risk across psychiatric conditions
Serotonin and dopamine pathway genes
Pharmacogenomics of psychotropic medicines (CYP2D6, CYP2C19)
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
Gut-brain axis mapping: neurotransmitter precursors, metabolite levels, and their correlations
For healthy aging and the review of medicines in later life
Epigenetic clocks, cardiometabolic and inflammatory markers, and a review of medicines for older adults against the AGS Beers Criteria. Not for time-critical or emergency decisions.
Epigenetic clocks from DNA methylation
Cardiometabolic and inflammatory markers
Review of medicines for older adults against the AGS Beers Criteria
Multi-system biomarker tensor (organic acids, microbiome, drug levels)
HOW YOUR PRECISION SUITE WORKS // FROM YOUR RESULTS TO YOUR PHYSICIAN
Your results in. Your physician’s dossier out.
A Precision Suite transforms your records and laboratory results into a complete evidence dossier for the physician who treats you. You bring the results. DeepSensi delivers the dossier. Your physician decides.
Choose your SuiteEleven Suites, one for each group of conditions. Standard Institutional Value $4,850, subsidized to $790 for Protocol Case Intake & 12-Month Longitudinal Access under DeepSensi PBC Charter. One Suite covers one patient.
Do the tests on your Suite’s listEvery Suite reads the gut-brain axis: urine organic acids and a metagenomic stool profile, plus the tests on its own list. Your physician orders them at any accredited laboratory. Every further result makes the dossier fuller, and your physician decides which additional tests fit your case.
Upload your resultsMy DeepSensi sorts them and strips your name and contact details on your own computer or phone, before anything travels.
Your dossier goes to your physicianDeepSensi sends it automatically. You receive your organized records, a confirmation, and the summary your physician has reviewed.
No physician yet? If you reside in the United States and do not have a physician who can receive the analysis, we can give you contact information for independent physicians who offer consultations by telehealth in the states where they are licensed. These physicians are not employed or controlled by DeepSensi. Each of them decides whether to accept you as a patient, sets their own fees, bills you directly and is responsible for your care. DeepSensi receives no payment from them, pays them nothing for seeing you and does not share in any fee you pay them. You are free to choose any other physician. This information is free, is not part of the price of a Suite and is available whether or not you buy one. It is not available to residents of California or Canada at this time. Terms of Service, 4.4
Precision Suite is clinical decision support software for licensed physicians. We believe it meets the non-device criteria of section 520(o)(1)(E) of the FD&C Act. FDA has not reviewed or confirmed this. It has not been cleared, approved, or otherwise authorized by FDA, and it makes no diagnostic accuracy claims. Regulatory status: deepsensi.com/regulatory
OSF RESEARCH COHORT (N=10,000) // PROTOCOL ALLOCATION // NO PAYMENT TODAY
Reserve your Precision Suite Cohort Allocation
DeepSensi Precision Suites launch in the United States in October 2026. Other countries will be activated sequentially. Joining the cohort wishlist reserves your priority allocation under the DeepSensi PBC Public Benefit Charter. No payment collected today.
THE TEST LISTS // ONE FOR EACH SUITE
The tests behind each Suite.
These are the inputs each Suite reads. Your own physician orders them at any accredited laboratory. Results go to your Suite as PDFs, and results you already have count. Two tests open every Suite, because every Suite reads the gut-brain axis.
EPI-Precision Suite™For drug-resistant epilepsy
Test
What it reads
Sample
Every Suite · the gut-brain axis
Urine organic acids (OAT)
Clostridial markers such as HPHPA and 4-cresol, mitochondrial and neurotransmitter markers
First-morning urine
Metagenomic stool profile
The gut microbiome at species level, with its functional genes
Stool
For drug-resistant epilepsy
Anti-seizure medicine levels
Real exposure and interactions across your current medicines
Inflammation linked to depression that resists treatment
Blood
PHQ-9 in the Suite
Depression severity, tracked over time
Questionnaire
Already done? When Suite opens, upload it via My DeepSensi Zero-PHI App
The full treatment history: every medicine, dose, duration and response, and earlier laboratory results.
PSYCH-Precision Suite™For psychiatric genomics
Test
What it reads
Sample
Every Suite · the gut-brain axis
Urine organic acids (OAT)
The kynurenine pathway and neurotransmitter metabolites
First-morning urine
Metagenomic stool profile
The gut microbiome at species level, with its functional genes
Stool
For psychiatric genomics
Pharmacogenomics: CYP2D6 and CYP2C19
How fast you clear most psychotropic medicines
Blood or saliva
Genome-wide genotyping or sequencing report
Polygenic risk across psychiatric conditions, and serotonin and dopamine pathway genes
Blood or saliva
Psychotropic medicine levels
Whether a medicine reached a working level
Blood, before the morning dose
Already done? When Suite opens, upload it via My DeepSensi Zero-PHI App
Earlier genetic and pharmacogenomic reports, and the full treatment history: every medicine, dose, duration and response.
LONGEVITY-Precision Suite™For healthy aging
Test
What it reads
Sample
Every Suite · the gut-brain axis
Urine organic acids (OAT)
Microbial, mitochondrial and neurotransmitter markers
First-morning urine
Metagenomic stool profile
The gut microbiome at species level, with its functional genes
Stool
For healthy aging
Epigenetic clock report (DNA methylation)
Biological age estimated from DNA methylation
Blood or saliva
Cardiometabolic panel: lipids, ApoB, Lp(a), HbA1c, fasting glucose and insulin
Cardiometabolic markers
Blood, fasting
High-sensitivity CRP
Low-grade inflammation
Blood
Every medicine and supplement, in one list
Read against the AGS Beers Criteria for older adults
From you
Medicine levels
Real exposure and interactions across the medicines you take
Blood, before the next dose
Already done? When Suite opens, upload it via My DeepSensi Zero-PHI App
Earlier laboratory results, earlier epigenetic or genetic reports, and every medicine with its dose.
Every further result makes the dossier fuller: your physician decides which additional tests fit your case. A Suite reads written reports and values, never images, raw instrument files or device exports. DeepSensi names no laboratory and takes nothing from any laboratory.
Clinical Workflow
How Dual-Governance Empowers Your Treating Doctor
Step 1 · Caregiver Intake
Upload Local Lab Results
Caregivers securely upload standardized lab panels (OAT, microbiome, routine blood work, drug levels) performed at any local CLIA/ISO-accredited clinical laboratory.
Step 2 · Cognitive OS Synthesis
Multi-Scale Tensor & Twin
DeepSensi builds the patient precision tensor (T_patient), simulates cross-system dynamics in the MASAI Digital Twin, and exposes hidden toxicities or metabolic blocks under deterministic bounds across 60+ integrated databases.
Step 3 · Doctor Co-Signature
Free Clinician Workbench
Your physician receives a structured, DSS-001 cross-verified Evidence Dossier in a free clinical workbench. The physician reviews the findings and co-signs the care plan, maintaining total legal and medical autonomy. Not for time-critical or emergency decisions.
Step 4 · What you receive
Your physician decides
Your physician decides what to share with you. The analysis stays with them until they do.
If the physician you name does not confirm receipt, the analysis is not opened.
MY DEEPSENSI APP // ZERO-PHI INTAKE // USPTO PATENT PENDING
Your identity never leaves your device.
Your records, made ready on your own device. My DeepSensi is the front door of the Cognitive Engine for patients and families: a desktop and mobile application that takes in records, laboratory PDFs and images, removes identifying details on the device, and turns years of paper into one complete, coded case.
Effortless intake
Drop in years of records, laboratory PDFs, and images. My DeepSensi reads them, orders them in time, and shows you what's missing.
Coded before it leaves
Names, numbers, and addresses are removed on your own computer or phone. The Cognitive Engine receives coded clinical content, never your identity. That is on-device intake, and it is the same under every plan.
One case, every device
Start on the desktop. Add a photo of a new result from your phone. One living case, always current.
Your name and contact details stay on your device.
DEEPSENSI // COUNTRY BY COUNTRY
What is available in your country
Precision Suites launch in October 2026 in the United States and Canada (except Quebec). Reservations open shortly, and they will set the order in which countries are activated. My DeepSensi is coming soon. Edge Node pre-orders in the United States, and free reservations everywhere else, open shortly.
Availability by country
Country or region
Precision Suite
Edge Node
My DeepSensi
USUnited States
Reservations open shortly
Pre-orders open shortly
Coming soon
CACanada
Reservations open shortly
Reservations open shortly
Coming soon
AUAustralia
Reservations open shortly
Reservations open shortly
Coming soon
+European Economic Area
Not available
Not available
Not available
+United Kingdom, Switzerland, mainland China, Thailand, Türkiye